Home » Stocks » ADTX

Aditx Therapeutics, Inc. (ADTX)

Stock Price: $2.59 USD -0.02 (-0.58%)
Updated Apr 19, 2021 2:37 PM EDT - Market open
Market Cap 37.24M
Revenue (ttm) n/a
Net Income (ttm) -9.15M
Shares Out 14.49M
EPS (ttm) -1.33
PE Ratio n/a
Forward PE 5.91
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $2.59
Previous Close $2.60
Change ($) -0.02
Change (%) -0.58%
Day's Open 2.64
Day's Range 2.49 - 2.67
Day's Volume 429,709
52-Week Range 1.62 - 9.58

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

MOUNTAIN VIEW, Calif., April 13, 2021 /PRNewswire/ -- Aditx Therapeutics, Inc. (Aditxt) (the "Company") (Nasdaq: ADTX), a biotech innovation company focused on improving the health of the immune system,...

6 days ago - PRNewsWire

MOUNTAIN VIEW, Calif., April 6, 2021 /PRNewswire/ -- Aditx Therapeutics, Inc. (Aditxt) (the "Company") (Nasdaq: ADTX), a biotech innovation company focused on improving the health of the immune system, ...

1 week ago - PRNewsWire

MOUNTAIN VIEW, Calif., April 1, 2021 /PRNewswire/ -- Aditx Therapeutics, Inc. (Aditxt) (the "Company") (Nasdaq: ADTX), a biotech innovation company focused on improving the health of the immune system, ...

2 weeks ago - PRNewsWire

Aditx Therapeutics Inc (NASDAQ: ADTX) is preparing its therapeutic program for psoriasis for First-In-Human clinical trials by the end of this year. The trials, which are planned to begin in Q4 2021, wi...

3 weeks ago - Benzinga

MOUNTAIN VIEW, Calif., March 24, 2021 /PRNewswire/ -- Aditx Therapeutics, Inc. (Aditxt) (the "Company") (Nasdaq: ADTX), a biotech innovation company focused on improving the health of the immune system,...

3 weeks ago - PRNewsWire

Mountain View, CA, March 04, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a biotech innovation company focused on improving the health o...

1 month ago - GlobeNewsWire

Dr. Tyan Will Lead and Advance Organ Transplantation Therapeutic Program

2 months ago - GlobeNewsWire

Balance Sheet Further Strengthened by Receipt of Additional $3.3 Million from Exercise of Existing Warrants

2 months ago - GlobeNewsWire

Shares of ADiTx Therapeutics Inc (NASDAQ: ADTX) are trading at a five-month high Thursday after ADiTx announced it would launch the AditxtScore Immune Monitoring Platform on Feb. 1. The initial applicat...

2 months ago - Benzinga

About ADTX

ADiTx Therapeutics, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune reprogramming and monitoring. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products ... [Read more...]

Industry
Biotechnology
IPO Date
Jun 30, 2020
Stock Exchange
NASDAQ
Ticker Symbol
ADTX
Full Company Profile

Financial Performance

Financial Statements